Gotowa bibliografia na temat „Conception de médicaments in silico”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Conception de médicaments in silico”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Conception de médicaments in silico"
Couvreur, Patrick. "Les nanotechnologies pour la conception de nouveaux médicaments". Biologie Aujourd'hui 206, nr 4 (2012): 237–48. http://dx.doi.org/10.1051/jbio/2012025.
Pełny tekst źródłaOpperdoes, FR. "Conception rationnelle de nouveaux médicaments contre la maladie du sommeil". médecine/sciences 11, nr 9 (1995): 1305. http://dx.doi.org/10.4267/10608/2451.
Pełny tekst źródłaVAILLANT, H., Y. RUELLE i JS CADWALLADER. "BREVES DE MEDECINE". EXERCER 34, nr 198 (1.12.2023): 479–80. http://dx.doi.org/10.56746/exercer.2023.198.479.
Pełny tekst źródłaClaude, Nancy, Françoise Goldfain-Blanc i André Guillouzo. "La place des méthodesin silico, in vitro, in omicdans l’évaluation de la sécurité des médicaments". médecine/sciences 25, nr 1 (styczeń 2009): 105–10. http://dx.doi.org/10.1051/medsci/2009251105.
Pełny tekst źródłaFournier, Chloé, David Feldman, Catherine Greffier, Isabelle Rouiller-Furic i Pierre Lombrail. "Conception d’un outil d’éducation thérapeutique sur les médicaments génériques : de l’idée à la mise en place". Education Thérapeutique du Patient - Therapeutic Patient Education 3, nr 2 (28.07.2011): S101—S110. http://dx.doi.org/10.1051/tpe/2011110.
Pełny tekst źródłaJose, J. "Bioanalyse en chimie médicinale : de la mise au point d’analyses à la conception évolutive de médicaments". Annales Pharmaceutiques Françaises 67, nr 6 (listopad 2009): 399–407. http://dx.doi.org/10.1016/j.pharma.2009.07.002.
Pełny tekst źródłaHibert, Marcel. "Approches moléculaires et thérapeutiques des interactions entre l’ocytocine et son récepteur". Biologie Aujourd’hui 216, nr 3-4 (2022): 125–30. http://dx.doi.org/10.1051/jbio/2022013.
Pełny tekst źródłaRomán-Alonso, G., F. Rojas-González, M. Aguilar-Cornejo, S. Cordero-Sánchez i M. A. Castro-García. "In-silico simulation of porous media: Conception and development of a greedy algorithm". Microporous and Mesoporous Materials 137, nr 1-3 (styczeń 2011): 18–31. http://dx.doi.org/10.1016/j.micromeso.2010.08.016.
Pełny tekst źródłaChames, Patrick, i Thierry Wurch. "Les anticorps et scaffold bispécifiques, des médicaments innovants en oncologie impliquant le ciblage des cellules immunitaires". médecine/sciences 35, nr 12 (grudzień 2019): 1072–82. http://dx.doi.org/10.1051/medsci/2019242.
Pełny tekst źródłaDuclos, Vincent. "La voie de l’intérieur". Diversité urbaine 9, nr 2 (11.03.2010): 51–71. http://dx.doi.org/10.7202/039387ar.
Pełny tekst źródłaRozprawy doktorskie na temat "Conception de médicaments in silico"
Jacq, Nicolas. "Recherche de médicaments in silico sur grilles de calcul contre des maladies négligées et émergentes". Clermont-Ferrand 2, 2006. http://www.theses.fr/2006CLF21715.
Pełny tekst źródłaMontes, Matthieu. "Développement et applications de méthodes de drug-design et de criblage in silico". Paris 5, 2007. http://www.theses.fr/2007PA05P611.
Pełny tekst źródłaVirtual ligand screening methods based on the structure of the receptor are extensively used to facilitate the discovery of lead compounds. Using different docking/scoring packages, we optimized a hierarchical virtual ligand screening protocol developed in our lab. This new protocol has been validated on different targets with different binding site properties. This multi-step hierarchical protocol has been applied to two targets of therapeutic importance, namely, the dual specificity phosphatase CDC25 and the 20S proteasome. Using ADME-tox filtered compound collections processed in our lab, we identified several new active molecules on these two difficult targets. These promising micromolar inhibitors displaying novel and growable scaffolds can lead to new potential drugs for cancer treatment
Schalon, Claire. "Comparaison in silico de sites de liaison de protéines". Strasbourg 1, 2008. http://www.theses.fr/2008STR13091.
Pełny tekst źródłaAfter the selection of different sets of proteins with a pharmacological interest (sc-PDB databank) and the identification of their binding sites, these sets have been used to validate and to do screenings with a structural alignment program, SiteAlign. SiteAlign use a discretized sphere and normalized scores to compare two binding sites. A scoring protocol, then the possible applications of the program have been determined. SiteAlign can be used for functional annotations of genomic proteins, for predictions of cross reactivity and predictions of ligands targets (experimental validation of this calculation). SiteAlign has then been used, in the chemogenomic part of the project, for studying in 3D the G-coupled protein receptors and for suggesting new ligands for orphan receptors. Last, SiteAlign has been used to compare the structural space of sc-PDB sites
Checa, Ruano Luis. "Structure-based design of antiviral drugs against respiratory viruses using in silico approaches". Electronic Thesis or Diss., Sorbonne université, 2024. https://accesdistant.sorbonne-universite.fr/login?url=https://theses-intra.sorbonne-universite.fr/2024SORUS0743.pdf.
Pełny tekst źródłaProtein-Protein interactions (PPI) play crucial roles in many biological pathways and are being increasingly explored as potential therapeutic targets, including for treating infectious diseases. However, designing small molecule modulators for PPI remains challenging as PPI interfaces have not evolved to bind small molecules like conventional drug targets such as enzymes or membrane receptors. Therefore, proof of their druggability must be made on a case-by-case basis. In this context, computational approaches can be useful in assisting the design of PPI modulators.This work aims to develop new in silico drug design protocols specifically tailored to PPI targets, with the goal of designing new antiviral drugs against two PPI targets: the respiratory syncytial virus (RSV) and the SARS-CoV-2
Fourches, Denis. "Modèles multiples en QSAR/QSPR : Développement de nouvelles approches et leurs applications au design "in silico" de nouveaux extractants de métaux, aux propriétés ADMETox ainsi qu'à différentes activités biologiques de molécules organiques". Université Louis Pasteur (Strasbourg) (1971-2008), 2007. http://www.theses.fr/2007STR13119.
Pełny tekst źródłaThis thesis work concerns the improvement of prediction performances of QSAR structureproperty models, using consensus modelling strategies based on fragment descriptors, and also, to their applications for « in silico » design of metal binders, ADMETox properties and different biological activities of organic compounds. In the first part, some important concepts and methodologies of chemoinformatics are described. In the second part, the ensemble of programs ISIDA (In Silico Design and Data Analysis) is introduced. During this thesis work, two consensus approaches have been suggested: the « Divide and Conquer » strategy and the Stepwise k- Nearest Neighbors approach. Applications of new strategies lead to significant improvement of predictions accuracy, compared to the conventional models. In the third part, all ISIDA methods have been successfully applied to model various chemical and biological properties. Experimentally proven predictions demonstrate the robustness of the methods
Villemagne, Baptiste. "Conception, synthèse et dévelopement d'inhibiteurs du répresseur transcriptionnel mycobactérien ETHR selon une approche par fragments. Une nouvelle approche dans la lutte contre la tuberculose". Thesis, Lille 2, 2012. http://www.theses.fr/2012LIL2S052/document.
Pełny tekst źródłaTuberculosis (TB) remains the leading cause of death due to a single infective agent with more than 1.5 million people killed each year. In 2011, the world health organization (WHO) estimated that one third of the world’s population is infected with Mycobacterium tuberculosis, the pathogen responsible for the disease. This phenomenon may be due to an explosive escalation of TB incidence that occurred in the 1980s due to the emergence of both resistant strains and HIV epidemic.In 2000, EthR, a mycobacterial transcriptional repressor, was identified as a key modulator of ethionamide (ETH) bioactivation. ETH is one of the main second-line drugs used to treat drug resistant strains. In 2009, it was shown that co-administration of ETH and drug-like inhibitors of EthR was able to boost ETH activity threefold in a mouse-model of TB-infection, thus validating the target for a new therapeutic strategy.This work deals with the discovery and optimisation of new EthR inhibitors, based on a small molecule, called a “fragment”, co-crystallized with the protein. We combined in silico screening, in vitro evaluation of the hit compounds, study of co-crystal structures and medicinal chemistry to develop three complementary approaches called “fragment growing”, “fragment merging” and “fragment linking” that led to the discovery of very potent inhibitors. Based on these results, we are currently selecting a potential candidate for new in vivo experiments
Vallet, Thibault. "Conception d'un outil d'évaluation de l'acceptabilité des médicaments". Thesis, Paris, ENSAM, 2017. http://www.theses.fr/2017ENAM0048/document.
Pełny tekst źródłaMedicine development must satisfy efficiency and safety objectives. Patient compliance with physician’s prescription is an essential condition to achieve these objectives. Patient acceptability of a medicine improves patient compliance and thus ensures drug success, in particular in paediatric and geriatric populations. Acceptability could be defined as the overall ability and willingness of the patient to use, and its care giver to administer, the medicine as intended. Acceptability is driven by the users’ and the products’ characteristics. Thus, designers have to consider the specific features of the targeted users to develop a medicine with the most adapted characteristics to reach the best acceptability. Evaluation of the acceptability should be an integral part of pharmaceutical and clinical development. Today, knowledge on this complex phenomenon is still fragmented and there are no internationally agreed methods available to assess this multidimensional concept. This document sets out the development of a validated tool, the acceptability reference framework, providing standardized medicines acceptability evaluation and relevant knowledge usable by designers from the early stage of medicine development. As this research was carried out in a medical field, we propose a formalized methodology transferable to other domains
Vallet, Thibault. "Conception d'un outil d'évaluation de l'acceptabilité des médicaments". Electronic Thesis or Diss., Paris, ENSAM, 2017. http://www.theses.fr/2017ENAM0048.
Pełny tekst źródłaMedicine development must satisfy efficiency and safety objectives. Patient compliance with physician’s prescription is an essential condition to achieve these objectives. Patient acceptability of a medicine improves patient compliance and thus ensures drug success, in particular in paediatric and geriatric populations. Acceptability could be defined as the overall ability and willingness of the patient to use, and its care giver to administer, the medicine as intended. Acceptability is driven by the users’ and the products’ characteristics. Thus, designers have to consider the specific features of the targeted users to develop a medicine with the most adapted characteristics to reach the best acceptability. Evaluation of the acceptability should be an integral part of pharmaceutical and clinical development. Today, knowledge on this complex phenomenon is still fragmented and there are no internationally agreed methods available to assess this multidimensional concept. This document sets out the development of a validated tool, the acceptability reference framework, providing standardized medicines acceptability evaluation and relevant knowledge usable by designers from the early stage of medicine development. As this research was carried out in a medical field, we propose a formalized methodology transferable to other domains
Baccouche, Rym. "Conception de ligands protéiques artificiels par ingénierie moléculaire in silico". Phd thesis, Université René Descartes - Paris V, 2012. http://tel.archives-ouvertes.fr/tel-00807525.
Pełny tekst źródłaAsses, Yasmine. "Conception par modélisation et criblage in silico d'inhibiteurs du récepteur c-Met". Phd thesis, Université Henri Poincaré - Nancy I, 2011. http://tel.archives-ouvertes.fr/tel-00653609.
Pełny tekst źródłaKsiążki na temat "Conception de médicaments in silico"
Darryl, León, i Markel Scott, red. In silico technologies in drug target identification and validation. Boca Raton: CRC Press, 2006.
Znajdź pełny tekst źródła1947-, Reid Ronald E., red. Peptide and protein drug analysis. New York: M. Dekker, 2000.
Znajdź pełny tekst źródłaSterility, sterilisation and sterility assurance for pharmaceuticals: Technology, validation and current regulations. Oxford: Woodhead Publishing Limited, 2013.
Znajdź pełny tekst źródłaDrug synthesis. Milton Keynes: Open University, 2009.
Znajdź pełny tekst źródłaV, Lees Graham, red. Drug discovery: From bedside to Wall Street. Amsterdam: Elsevier Academic, 2006.
Znajdź pełny tekst źródłaMayforth, Ruth D. Designing antibodies. San Diego: Academic Press, Inc., 1993.
Znajdź pełny tekst źródłade, Waterbeemd Han van, red. Chemometric methods in molecular design. Weinheim: VCH, 1995.
Znajdź pełny tekst źródłaBiochips As Pathways To Drug Discovery. Hoboken: CRC Press, 2006.
Znajdź pełny tekst źródłaNanotechnology and drug delivery. Boca Raton: Taylor & Francis, 2014.
Znajdź pełny tekst źródłaW, Ellis Ronald, i Brodeur Bernard R, red. New bacterial vaccines. Georgetown, Tex: Landes Bioscience/Eurekah.com, 2003.
Znajdź pełny tekst źródłaCzęści książek na temat "Conception de médicaments in silico"
Balansard, Guy. "Conception of an antimalaria medicinal product from plants used in traditional medicine". W Des sources du savoir aux médicaments du futur, 243–44. IRD Éditions, 2002. http://dx.doi.org/10.4000/books.irdeditions.7234.
Pełny tekst źródłaBalansard, Guy. "Conception d’un médicament antimalarique à base de plantes issues de la médecine traditionnelle". W Des sources du savoir aux médicaments du futur, 241–42. IRD Éditions, 2002. http://dx.doi.org/10.4000/books.irdeditions.7233.
Pełny tekst źródła